Company chart and information is provided by TradingView based on 15-minute-delayed data.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
| Website: | www.relmada.com |
| Email: | straversa@relmada.com |
| Main Phone: | +1 646 876-3459 |
| Address: | 880 Third Avenue |
| Address 2: | 12th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10022 |
| Exchange: | NGS |
| CEO: | Sergio Traversa |
| Employees: | 14 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
